XORTX Therapeutics

XORTX Therapeutics is a late-stage clinical pharmaceutical company developing therapies for hyperuricemia-related disease, with a portfolio spanning gout and progressive kidney disease. Its lead program, XRx-026, is built on XORLO, a proprietary formulation of the xanthine oxidase inhibitor oxypurinol, and is aimed at gout patients who cannot tolerate or do not respond adequately to existing urate-lowering therapy: allopurinol is not tolerated by an estimated 3-5% of patients, and febuxostat carries a boxed warning for cardiovascular risk. The company has outlined a regulatory pathway in which an Investigational New Drug application for XRx-026 is targeted to the fourth quarter of 2026, followed by the two-part XRX-OXY-102 study to characterize pharmacokinetics and efficacy and commercial-scale manufacturing for a first year of launch, with an NDA submission targeted approximately one year out. Earlier-stage assets include XRx-008 for autosomal dominant polycystic kidney disease and XRx-101 for acute kidney injury associated with respiratory viral infection, including sepsis.